MOLOGEN AG: Impressive extended EnanDIM(R) preclinical data presented at the ITOC6 conference

DGAP-News: MOLOGEN AG / Key word(s): Conference

15.04.2019 / 10:00

The issuer is solely responsible for the content of this announcement.


Press release N 8 / 2019 of 15 April 2019

MOLOGEN AG: Impressive extended EnanDIM(R) preclinical data presented at the ITOC6 conference

Berlin, 15 April 2019 – The biopharmaceutical company MOLOGEN AG presented data of its EnanDIM(R)molecules, a new generation of potent non chemically-modified TLR9 agonists, at the ITOC6 CONFERENCE 2019, (THE 6TH LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE) in Vienna, Austria (11 – 13 April 2019). In murine tumor models, monotherapy with one of its EnanDIM(R) candidates induced persistent immune memory which results not only in specific immune responses against the original tumor but also in recognition and killing of tumors of different origin.

In previous studies it was already shown that in murine tumor models monotherapy with EnanDIM(R) candidates resultedin a beneficial modulation of the tumor microenvironment (TME) translating into remarkable anti-tumor effects with remarkably increased survival rates.

One EnanDIM(R) candidate led to complete tumor regression in the majority of mice and a subsequent re-challenge with the same tumor cells resulted in tumor rejection without further treatment. This indicates a sustained anti-tumor memory of the immune system. Notably, in a breast cancer model a re-challenge of surviving mice with malignant cells from a different tumor, colon cancer, led to rejection of these malignant cells as well. The broad anti-tumor immune response induced by EnanDIM(R) was confirmed and extended in the surviving mice by apparent immune recognition and rejection of not only the initial breast cancer but also tumor cells of different origin (colon cancer, renal cancer). Thus, the data presented prove impressively the EnanDIM(R)-induced generation of a systemic immune memory against shared tumor antigens expressed across various tumor indications and therefore provide an excellent basis for further development of EnanDIM(R)in cancer.

For more information on ITOC6 CONFERENCE (2019) please visit the website:
http://itoc-conference.eu/itoc6-conference-2019

MOLOGEN AG
MOLOGEN AG is a biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.

The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM(R).

The immunotherapeutic agent lefitolimod is the Company’s lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in extensive-stage small cell lung cancer (ES-SCLC) and the data from the extension phase of the TEACH study in HIV have been published.
In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.
MOLOGEN’s pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.

MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.

www.mologen.com

Contact
Claudia Nickolaus

Head of Investor Relations & Corporate Communications
Tel: +49 – 30 – 84 17 88 – 38
Fax: +49 – 30 – 84 17 88 – 50
investor@mologen.com

Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.


15.04.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: presse@mologen.com
Internet: www.mologen.com
ISIN: DE000A2LQ900
WKN: A2LQ90
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 799821

 
End of News DGAP News Service

show this